1. Home
  2. VIR vs SHCO Comparison

VIR vs SHCO Comparison

Compare VIR & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • SHCO
  • Stock Information
  • Founded
  • VIR 2016
  • SHCO 1995
  • Country
  • VIR United States
  • SHCO United Kingdom
  • Employees
  • VIR N/A
  • SHCO N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • VIR Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • VIR Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • VIR 844.9M
  • SHCO 1.0B
  • IPO Year
  • VIR 2019
  • SHCO 2021
  • Fundamental
  • Price
  • VIR $5.10
  • SHCO $7.57
  • Analyst Decision
  • VIR Strong Buy
  • SHCO Buy
  • Analyst Count
  • VIR 7
  • SHCO 2
  • Target Price
  • VIR $32.86
  • SHCO $7.25
  • AVG Volume (30 Days)
  • VIR 1.1M
  • SHCO 197.3K
  • Earning Date
  • VIR 07-31-2025
  • SHCO 08-08-2025
  • Dividend Yield
  • VIR N/A
  • SHCO N/A
  • EPS Growth
  • VIR N/A
  • SHCO N/A
  • EPS
  • VIR N/A
  • SHCO N/A
  • Revenue
  • VIR $20,861,000.00
  • SHCO $1,224,734,000.00
  • Revenue This Year
  • VIR N/A
  • SHCO $8.99
  • Revenue Next Year
  • VIR N/A
  • SHCO $6.02
  • P/E Ratio
  • VIR N/A
  • SHCO N/A
  • Revenue Growth
  • VIR N/A
  • SHCO 8.21
  • 52 Week Low
  • VIR $4.32
  • SHCO $4.43
  • 52 Week High
  • VIR $14.45
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • VIR 43.30
  • SHCO 70.83
  • Support Level
  • VIR $5.00
  • SHCO $7.21
  • Resistance Level
  • VIR $5.35
  • SHCO $7.46
  • Average True Range (ATR)
  • VIR 0.23
  • SHCO 0.25
  • MACD
  • VIR -0.01
  • SHCO 0.04
  • Stochastic Oscillator
  • VIR 9.56
  • SHCO 94.14

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

Share on Social Networks: